专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20110054194A1 Halichondrin B Analogs 有权
标题翻译： Halichondrin B类似物
公开(公告)号：US20110054194A1
公开(公告)日：2011-03-03
申请号：US12936056
申请日：2009-04-03
申请人： Yongbo Hu
发明人： Yongbo Hu
IPC分类号： C07D493/22
CPC分类号： C07D493/22 , C07B2200/13
摘要： The invention includes halichondrin B analogs having pharmaceutical activity; in some cases, crystalline forms thereof, and in some cases, halichondrin B analogs having a further utility as synthetic intermediates.
摘要翻译：本发明包括具有药物活性的软骨素B类似物; 在一些情况下，其结晶形式，并且在一些情况下，具有作为合成中间体的进一步实用性的软绵绵蛋白B类似物。

12. 发明申请

US20070244140A1 Anilino-pyrimidine phenyl and benzothiophene analogs 审中-公开
标题翻译：苯胺基嘧啶苯基和苯并噻吩类似物
公开(公告)号：US20070244140A1
公开(公告)日：2007-10-18
申请号：US11786380
申请日：2007-04-10
申请人： Yongbo Hu , Fuk-Wah Sum , Martin Di Grandi , Emily Norton
发明人： Yongbo Hu , Fuk-Wah Sum , Martin Di Grandi , Emily Norton
IPC分类号： A61K31/506 , C07D403/02 , A61K31/505 , C07D239/32
CPC分类号： C07D409/12 , C07D239/42 , C07D409/04 , C07D409/14
摘要： The present invention relates to compounds of formula III: wherein R2, R3, R5 and R6 are as defined herein.
摘要翻译：本发明涉及式III化合物：其中R 2，R 3，R 5和R 6，如本文所定义。

13. 发明申请

US20110172427A1 PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS 审中-公开
标题翻译：制备某些化合物的方法
公开(公告)号：US20110172427A1
公开(公告)日：2011-07-14
申请号：US13060979
申请日：2009-08-26
申请人： Taiju Nakamura , Masaaki Matsuda , Yongbo Hu , Daiju Hasegawa , Yorihisa Hoshino , Kazato Inanaga , Minetaka Isomura , Nobuaki Sato , Kazuhiro Yoshizawa , George A. Moniz , Gordon D. Wilkie , Francis G. Fang , Yoshihiro Nishikawa
发明人： Taiju Nakamura , Masaaki Matsuda , Yongbo Hu , Daiju Hasegawa , Yorihisa Hoshino , Kazato Inanaga , Minetaka Isomura , Nobuaki Sato , Kazuhiro Yoshizawa , George A. Moniz , Gordon D. Wilkie , Francis G. Fang , Yoshihiro Nishikawa
IPC分类号： C07D471/04 , C07C257/06 , C07D401/14 , C07D401/04
CPC分类号： C07D471/04 , C07C257/06 , C07D401/04
摘要： This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.
摘要翻译：本发明涉及如下所示的通过化合物11和12的混合物的新合成，中间体和前体。它还涉及立体异构体混合物的拆分以提供基本的立体化学纯度化合物12.本发明的合成包括如下所示的化合物7和化合物10的制备及其制备化合物11和化合物12的混合物的反应。

14. 发明授权

US07786257B2 Signal-1/signal-2 bifunctional peptide inhibitors 有权
标题翻译： Signal-1 /信号-2双功能肽抑制剂
公开(公告)号：US07786257B2
公开(公告)日：2010-08-31
申请号：US09739466
申请日：2000-12-18
申请人： Joseph S. Murray , Teruna J. Siahaan , Yongbo Hu
发明人： Joseph S. Murray , Teruna J. Siahaan , Yongbo Hu
IPC分类号： C07K14/00
CPC分类号： A61K39/001 , A61K2039/57 , C07K14/70553 , C07K16/2821 , C07K16/2833 , C07K2319/00 , C12N9/88
摘要： A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a major histocompatibility complex on an antigen presenting cell, and wherein said B chain is capable of binding with a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include an X chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include an A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptor moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue. Advantageously, the novel peptide sequence is capable of shifting a type-1 immune response to a type-2 immune response or from a type-2 immune response to a type-1 immune response.
摘要翻译：一种具有通式AB的新型肽序列，其中A和B各自表示氨基酸残基，其中所述A链能够与抗原呈递细胞上的主要组织相容性复合物结合，并且其中所述B链能够与抗原呈递细胞上的Signal-2受体结合。肽序列的优选形式还包括位于A链和B链之间的X链。此外，优选的形式包括与Signal-1部分具有至少约10％序列同源性的A链或者是Signal-1部分的肽模拟物，所述B链与Signal-2具有至少10％的序列同源性受体部分，或是Signal-2受体部分的肽模拟物，并且其中X链具有至少一个氨基酸残基，或者是该氨基酸残基的肽模拟物。有利地，新的肽序列能够将1型免疫应答转变为2型免疫应答或从2型免疫应答转移到1型免疫应答。

15. 发明申请

US20050107585A1 Signal-1/signal-2 bifunctional peptide inhibitors 有权
标题翻译： Signal-1 /信号-2双功能肽抑制剂
公开(公告)号：US20050107585A1
公开(公告)日：2005-05-19
申请号：US09739466
申请日：2000-12-18
申请人： Joseph Murray , Teruna Siahaan , Yongbo Hu
发明人： Joseph Murray , Teruna Siahaan , Yongbo Hu
IPC分类号： A61K38/00 , A61P37/02 , C07K7/06 , C07K7/08 , C07K14/705 , C07K16/28 , C07K19/00 , C12N9/88
CPC分类号： A61K39/001 , A61K2039/57 , C07K14/70553 , C07K16/2821 , C07K16/2833 , C07K2319/00 , C12N9/88
摘要： A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a major histocompatibility complex on an antigen presenting cell, and wherein said B chain is capable of binding with a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include an X chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include an A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptor moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue. Advantageously, the novel peptide sequence is capable of shifting a type-1 immune response to a type-2 immune response or from a type-2 immune response to a type-1 immune response.
摘要翻译：一种具有通式AB的新型肽序列，其中A和B各自表示氨基酸残基，其中所述A链能够与抗原呈递细胞上的主要组织相容性复合物结合，并且其中所述B链能够与抗原呈递细胞上的Signal-2受体结合。肽序列的优选形式还包括位于A链和B链之间的X链。此外，优选的形式包括与Signal-1部分具有至少约10％序列同源性的A链或者是Signal-1部分的肽模拟物，所述B链与Signal-2具有至少10％的序列同源性受体部分，或是Signal-2受体部分的肽模拟物，并且其中X链具有至少一个氨基酸残基，或者是该氨基酸残基的肽模拟物。有利地，新的肽序列能够将1型免疫应答转变为2型免疫应答或从2型免疫应答转移到1型免疫应答。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式